Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Pulmonary Arterial Hypertension-Pipeline Review, H1 2015

Pulmonary Arterial Hypertension-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Pulmonary Arterial Hypertension-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Pulmonary Arterial Hypertension-Pipeline Review, H1 2015', provides an overview of the Pulmonary Arterial Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pulmonary Arterial Hypertension and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Pulmonary Arterial Hypertension Overview 8

Therapeutics Development 9

Pipeline Products for Pulmonary Arterial Hypertension-Overview 9

Pipeline Products for Pulmonary Arterial Hypertension-Comparative Analysis 10

Pulmonary Arterial Hypertension-Therapeutics under Development by Companies 11

Pulmonary Arterial Hypertension-Therapeutics under Investigation by Universities/Institutes 15

Pulmonary Arterial Hypertension-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Pulmonary Arterial Hypertension-Products under Development by Companies 19

Pulmonary Arterial Hypertension-Products under Investigation by Universities/Institutes 23

Pulmonary Arterial Hypertension-Companies Involved in Therapeutics Development 24

Actelion Ltd 24

APT Therapeutics, Inc. 25

Arena Pharmaceuticals, Inc. 26

Asahi Kasei Pharma Corp. 27

Ascendis Pharma A/S 28

Bial-Portela & Ca, S.A. 29

Cardioxyl Pharmaceuticals, Inc. 30

Carolus Therapeutics, Inc. 31

Celladon Corporation 32

Celsion Corporation 33

Corridor Pharmaceuticals Inc. 34

Cytokinetics, Inc. 35

Eli Lilly and Company 36

Gilead Sciences, Inc. 37

HanAll Biopharma Co., Ltd. 38

Insmed Incorporated 39

Ironwood Pharmaceuticals, Inc. 40

Lacer, S.A. 41

Longevity Biotech, Inc 42

LTT Bio-Pharma Co., Ltd. 43

Mast Therapeutics, Inc. 44

Mezzion Pharma Co. Ltd. 45

miRagen Therapeutics, Inc. 46

Nippon Shinyaku Co., Ltd. 47

Novartis AG 48

PharmaIN Corporation 49

PhaseBio Pharmaceuticals, Inc. 50

Pluristem Therapeutics Inc. 51

Proteo, Inc. 52

Reata Pharmaceuticals, Inc. 53

Sagene Pharmaceuticals, Inc. 54

Silence Therapeutics plc 55

Sinoxa Pharma GmbH 56

Suda Ltd 57

Therametrics holding AG 58

Toray Industries, Inc. 59

United Therapeutics Corporation 60

Pulmonary Arterial Hypertension-Therapeutics Assessment 61

Assessment by Monotherapy Products 61

Assessment by Combination Products 62

Assessment by Target 63

Assessment by Mechanism of Action 66

Assessment by Route of Administration 69

Assessment by Molecule Type 71

Drug Profiles 73

(allopurinol + apocynin)-Drug Profile 73

(chlorthalidone + valsartan)-Drug Profile 74

ACP-009-Drug Profile 75

Antibody for Cancer and PAH-Drug Profile 76

Antibody for Pulmonary Arterial Hypertension-Drug Profile 77

APT-102-Drug Profile 78

bardoxolone methyl-Drug Profile 80

beraprost sodium nanoparticles SR-Drug Profile 83

beraprost sodium SR-Drug Profile 84

BIA-51058-Drug Profile 86

bosentan CR-Drug Profile 87

CT-2009-Drug Profile 88

DasKloster-1000-01-Drug Profile 89

Elafin-Drug Profile 91

esuberaprost sodium-Drug Profile 94

fasudil-Drug Profile 95

GS-4997-Drug Profile 96

imatinib mesylate-Drug Profile 97

IW-1973-Drug Profile 99

LA-419-Drug Profile 100

lisuride-Drug Profile 101

macitentan-Drug Profile 103

Mydicar-Drug Profile 106

Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension-Drug Profile 108

Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension-Drug Profile 109

PB-1046-Drug Profile 110

PB-1120-Drug Profile 112

Peptide to Antagonize Urotensin-II Receptor for PAH-Drug Profile 113

PGC-VIP-Drug Profile 114

PK-10453-Drug Profile 115

R-190-Drug Profile 116

ralinepag-Drug Profile 118

RNAi Oligonucleotide to Inhibit miR-145 for PAH-Drug Profile 120

selegiline + PDE-5 Inhibitor-Drug Profile 121

selexipag-Drug Profile 122

Small Molecule for Pulmonary Arterial Hypertension-Drug Profile 124

Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia-Drug Profile 125

Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction-Drug Profile 126

Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension-Drug Profile 127

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension-Drug Profile 128

Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension-Drug Profile 129

Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension-Drug Profile 130

sodium nitrite-Drug Profile 131

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 133

SUD-004-Drug Profile 135

Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension-Drug Profile 136

tadalafil-Drug Profile 137

TPN-171-Drug Profile 139

treprostinil diolamine-Drug Profile 140

TXA-127-Drug Profile 141

udenafil-Drug Profile 143

Pulmonary Arterial Hypertension-Recent Pipeline Updates 145

Pulmonary Arterial Hypertension-Dormant Projects 168

Pulmonary Arterial Hypertension-Discontinued Products 169

Pulmonary Arterial Hypertension-Product Development Milestones 170

Featured News & Press Releases 170

Appendix 176

Methodology 176

Coverage 176

Secondary Research 176

Primary Research 176

Expert Panel Validation 176

Contact Us 176

Disclaimer 177

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2015 13

Number of Products under Development for Pulmonary Arterial Hypertension-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Development by Companies, H1 2015 (Contd..3) 26

Products under Investigation by Universities/Institutes, H1 2015 27

Pulmonary Arterial Hypertension-Pipeline by Actelion Ltd, H1 2015 28

Pulmonary Arterial Hypertension-Pipeline by APT Therapeutics, Inc., H1 2015 29

Pulmonary Arterial Hypertension-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 30

Pulmonary Arterial Hypertension-Pipeline by Asahi Kasei Pharma Corp., H1 2015 31

Pulmonary Arterial Hypertension-Pipeline by Ascendis Pharma A/S, H1 2015 32

Pulmonary Arterial Hypertension-Pipeline by Bial-Portela & Ca, S.A., H1 2015 33

Pulmonary Arterial Hypertension-Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 34

Pulmonary Arterial Hypertension-Pipeline by Carolus Therapeutics, Inc., H1 2015 35

Pulmonary Arterial Hypertension-Pipeline by Celladon Corporation, H1 2015 36

Pulmonary Arterial Hypertension-Pipeline by Celsion Corporation, H1 2015 37

Pulmonary Arterial Hypertension-Pipeline by Corridor Pharmaceuticals Inc., H1 2015 38

Pulmonary Arterial Hypertension-Pipeline by Cytokinetics, Inc., H1 2015 39

Pulmonary Arterial Hypertension-Pipeline by Eli Lilly and Company, H1 2015 40

Pulmonary Arterial Hypertension-Pipeline by Gilead Sciences, Inc., H1 2015 41

Pulmonary Arterial Hypertension-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 42

Pulmonary Arterial Hypertension-Pipeline by Insmed Incorporated, H1 2015 43

Pulmonary Arterial Hypertension-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 44

Pulmonary Arterial Hypertension-Pipeline by Lacer, S.A., H1 2015 45

Pulmonary Arterial Hypertension-Pipeline by Longevity Biotech, Inc, H1 2015 46

Pulmonary Arterial Hypertension-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 47

Pulmonary Arterial Hypertension-Pipeline by Mast Therapeutics, Inc., H1 2015 48

Pulmonary Arterial Hypertension-Pipeline by Mezzion Pharma Co. Ltd., H1 2015 49

Pulmonary Arterial Hypertension-Pipeline by miRagen Therapeutics, Inc., H1 2015 50

Pulmonary Arterial Hypertension-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 51

Pulmonary Arterial Hypertension-Pipeline by Novartis AG, H1 2015 52

Pulmonary Arterial Hypertension-Pipeline by PharmaIN Corporation, H1 2015 53

Pulmonary Arterial Hypertension-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 54

Pulmonary Arterial Hypertension-Pipeline by Pluristem Therapeutics Inc., H1 2015 55

Pulmonary Arterial Hypertension-Pipeline by Proteo, Inc., H1 2015 56

Pulmonary Arterial Hypertension-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 57

Pulmonary Arterial Hypertension-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 58

Pulmonary Arterial Hypertension-Pipeline by Silence Therapeutics plc, H1 2015 59

Pulmonary Arterial Hypertension-Pipeline by Sinoxa Pharma GmbH, H1 2015 60

Pulmonary Arterial Hypertension-Pipeline by Suda Ltd, H1 2015 61

Pulmonary Arterial Hypertension-Pipeline by Therametrics holding AG, H1 2015 62

Pulmonary Arterial Hypertension-Pipeline by Toray Industries, Inc., H1 2015 63

Pulmonary Arterial Hypertension-Pipeline by United Therapeutics Corporation, H1 2015 64

Assessment by Monotherapy Products, H1 2015 65

Assessment by Combination Products, H1 2015 66

Number of Products by Stage and Target, H1 2015 68

Number of Products by Stage and Mechanism of Action, H1 2015 71

Number of Products by Stage and Route of Administration, H1 2015 74

Number of Products by Stage and Molecule Type, H1 2015 76

Pulmonary Arterial Hypertension Therapeutics-Recent Pipeline Updates, H1 2015 149

Pulmonary Arterial Hypertension-Dormant Projects, H1 2015 172

Pulmonary Arterial Hypertension-Discontinued Products, H1 2015 173

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2015 13

Number of Products under Development for Pulmonary Arterial Hypertension-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Late Stage Development, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 21

Comparative Analysis by Early Stage Products, H1 2015 22

Assessment by Monotherapy Products, H1 2015 65

Assessment by Combination Products, H1 2015 66

Number of Products by Top 10 Targets, H1 2015 67

Number of Products by Stage and Top 10 Targets, H1 2015 67

Number of Products by Top 10 Mechanism of Actions, H1 2015 70

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 70

Number of Products by Top 10 Routes of Administration, H1 2015 73

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 74

Number of Products by Top 10 Molecule Types, H1 2015 75

Number of Products by Stage and Top 10 Molecule Types, H1 2015 76

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actelion Ltd

APT Therapeutics, Inc.

Arena Pharmaceuticals, Inc.

Asahi Kasei Pharma Corp.

Ascendis Pharma A/S

Bial - Portela & Ca, S.A.

Cardioxyl Pharmaceuticals, Inc.

Carolus Therapeutics, Inc.

Celladon Corporation

Celsion Corporation

Corridor Pharmaceuticals Inc.

Cytokinetics, Inc.

Eli Lilly and Company

Gilead Sciences, Inc.

HanAll Biopharma Co., Ltd.

Insmed Incorporated

Ironwood Pharmaceuticals, Inc.

Lacer, S.A.

Longevity Biotech, Inc

LTT Bio-Pharma Co., Ltd.

Mast Therapeutics, Inc.

Mezzion Pharma Co. Ltd.

miRagen Therapeutics, Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

PharmaIN Corporation

PhaseBio Pharmaceuticals, Inc.

Pluristem Therapeutics Inc.

Proteo, Inc.

Reata Pharmaceuticals, Inc.

Sagene Pharmaceuticals, Inc.

Silence Therapeutics plc

Sinoxa Pharma GmbH

Suda Ltd

Therametrics holding AG

Toray Industries, Inc.

United Therapeutics Corporation

Pulmonary Arterial Hypertension Therapeutic Products under Development, Key Players in Pulmonary Arterial Hypertension Therapeutics, Pulmonary Arterial Hypertension Pipeline Overview, Pulmonary Arterial Hypertension Pipeline, Pulmonary Arterial Hypertension Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com